retatrutide type 2 diabetes phase 2 results 2024 2025 study sees significant weight loss in obesity drug study Retatrutide hits 28% weight loss

The approval of Mounjaro is an exciting step forward for people living with type 2 diabetes given the results seen in these clinical trials. Patrick Archdeacon, MD, associate director of the Division of Diabetes, Lipid Disorders and Obesity within the FDAs Center for Drug Evaluation and Research, also commented on the approval in an agency statement

These products typically claim to support or stimulate GLP1, but are not supported by randomized controlled trials demonstrating increased GLP1 levels or weight loss or glycemic benefits in humans

Look for cushions with removable, washable covers for hygiene

Were here to support your wellness journey, one strip at a time

Conclusion In conclusion, the current knowledge of MIS-C is still ongoing

Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from global burden of disease 2009-2019